Kazunori Akimoto
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Kazunori Akimoto has a total of 151 co-authors. Here are the top co-authors by number of shared publications:
Shoma Tamori
Department of Medicinal and Life Sciences, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Tokyo, Japan
21 shared publicationsShigeo Ohno
Institute for Diseases of Old Age, Juntendo University School of Medicine, Tokyo, Japan
18 shared publicationsAyaka Ozaki
Department of Medicinal and Life Sciences, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Tokyo, Japan
17 shared publicationsKazunori Sasaki
Institute for Diseases of Old Age, Juntendo University School of Medicine, Tokyo, Japan
15 shared publicationsKeiko Sato
Research Division of Medical Data Science, Research Institute for Science and Technology, Tokyo University of Science, Chiba, Japan
14 shared publicationsChotaro Onaga
Department of Medicinal and Life Sciences, Faculty of Pharmaceutical Sciences, Tokyo University of Science, Noda, Chiba 278‑8510, Japan
13 shared publications
Latest Publications
- Open Access
- 29 June 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (6) , e0352254
Cell–cell junction gene signatures as subtype-specific prognostic biomarkers in breast cancer
Cell–cell junctions (CCJs) are essential for maintaining epithelial integrity, and adhesion-related molecules have long been implicated in breast cancer progression. However, the subtype-specific prognostic significance of CCJ-related gene expression patterns within individual intrinsic breast cancer subtypes has not been systematically characterized. We analyzed 179 genes annotated to the Gene Ontology term “cell–cell junction organization” (GO:0045216) across intrinsic breast cancer subtypes using the METABRIC and The Cancer Genome Atlas (TCGA) datasets. Subtype-specific prognostic CCJ genes were identified using multivariate Cox proportional hazards models for disease-specific survival and integrated into CCJ gene expression signatures. The prognostic performance was validated in an independent cohort (SCAN-B). Elevated CCJ signature scores were associated with poorer survival across subtypes, with particularly strong effects in Luminal B (LumB) and Basal-like (Basal) tumors. Person-year analyses indicated that high CCJ scores predicted an increased incidence of early recurrence (0–5 years) in these aggressive subtypes. Pathway enrichment analyses revealed that high-score tumors exhibited upregulation of extracellular matrix organization and matrisome-related pathways. Single-cell RNA sequencing further demonstrated that LumB CCJ genes (e.g., PARD6B , CDH3 ) were predominantly expressed in tumor epithelial cells, whereas the Basal CCJ signature reflected contributions from epithelial (e.g., MARVELD2 ) and endothelial (e.g., RAMP2 ) cells. Collectively, CCJ signatures stratify prognosis and capture subtype-specific cellular and microenvironmental features in breast cancer.
- 29 June 2026
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 21 (6) , e0352254
Open AccessCell–cell junction gene signatures as subtype-specific prognostic biomarkers in breast cancer
Cell–cell junctions (CCJs) are essential for maintaining epithelial integrity, and adhesion-related molecules have long been implicated in breast cancer progression. However, the subtype-specific prognostic significance of CCJ-related gene expression patterns within individual intrinsic breast cancer subtypes has not been systematically characterized. We analyzed 179 genes annotated to the Gene Ontology term “cell–cell junction organization” (GO:0045216) across intrinsic breast cancer subtypes using the METABRIC and The Cancer Genome Atlas (TCGA) datasets. Subtype-specific prognostic CCJ genes were identified using multivariate Cox proportional hazards models for disease-specific survival and integrated into CCJ gene expression signatures. The prognostic performance was validated in an independent cohort (SCAN-B). Elevated CCJ signature scores were associated with poorer survival across subtypes, with particularly strong effects in Luminal B (LumB) and Basal-like (Basal) tumors. Person-year analyses indicated that high CCJ scores predicted an increased incidence of early recurrence (0–5 years) in these aggressive subtypes. Pathway enrichment analyses revealed that high-score tumors exhibited upregulation of extracellular matrix organization and matrisome-related pathways. Single-cell RNA sequencing further demonstrated that LumB CCJ genes (e.g., PARD6B , CDH3 ) were predominantly expressed in tumor epithelial cells, whereas the Basal CCJ signature reflected contributions from epithelial (e.g., MARVELD2 ) and endothelial (e.g., RAMP2 ) cells. Collectively, CCJ signatures stratify prognosis and capture subtype-specific cellular and microenvironmental features in breast cancer.
- Open Access
- 23 June 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (13) , 5646
Auranofin Suppresses Cancer Cell Invasion by Inhibiting Heparanase-1 Expression via the aPKC–NF-κB Pathway
Heparanase 1 (HPSE1) is the only mammalian endoglycosidase that cleaves heparan sulfate (HS), a glycosaminoglycan (GAG), and is frequently upregulated in cancers, thereby promoting tumor progression. Despite extensive efforts to develop inhibitors of its HS-degrading activity, its non-enzymatic functions limit therapeutic efficacy and pose a major challenge for therapeutic development. Thus, inhibiting HPSE1 expression is critical for controlling its enzymatic and non-enzymatic functions; however, no FDA-approved inhibitors are currently available. Here, we identify auranofin (AUF), an oral gold-containing drug used to treat rheumatoid arthritis, as a potent inhibitor of HPSE1 promoter activity. High-throughput screening revealed that an atypical protein kinase C (aPKC)–NF-κB signaling axis is a key regulator of HPSE1 expression. Notably, AUF treatment reduced HPSE1 expression and significantly suppressed the invasive capacity of MDA-MB-231 cells in a Transwell migration assay. We then investigated the role of HPSE1 in the invasive activity of MDA-MB-231 cells, which produce higher levels of hyaluronan (HA) and HS than non-invasive cells. Neither HS degradation, HA supplementation in Matrigel during Transwell migration, nor HPSE1 overexpression alone was sufficient to drive invasion, suggesting that invasive capacity depends on mesenchymal features and coordinated induction of HPSE1 and GAGs rather than HS degradation. Collectively, our findings demonstrate that AUF-mediated inhibition of aPKC suppresses HPSE1 expression, thereby inhibiting both its enzymatic and non-enzymatic functions and limiting cancer progression, metastasis, and angiogenesis. These results highlight the therapeutic potential of AUF for targeting HPSE1-driven tumor progression and support its repurposing for cancer treatment.
- 23 June 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (13) , 5646
Open AccessAuranofin Suppresses Cancer Cell Invasion by Inhibiting Heparanase-1 Expression via the aPKC–NF-κB Pathway
Heparanase 1 (HPSE1) is the only mammalian endoglycosidase that cleaves heparan sulfate (HS), a glycosaminoglycan (GAG), and is frequently upregulated in cancers, thereby promoting tumor progression. Despite extensive efforts to develop inhibitors of its HS-degrading activity, its non-enzymatic functions limit therapeutic efficacy and pose a major challenge for therapeutic development. Thus, inhibiting HPSE1 expression is critical for controlling its enzymatic and non-enzymatic functions; however, no FDA-approved inhibitors are currently available. Here, we identify auranofin (AUF), an oral gold-containing drug used to treat rheumatoid arthritis, as a potent inhibitor of HPSE1 promoter activity. High-throughput screening revealed that an atypical protein kinase C (aPKC)–NF-κB signaling axis is a key regulator of HPSE1 expression. Notably, AUF treatment reduced HPSE1 expression and significantly suppressed the invasive capacity of MDA-MB-231 cells in a Transwell migration assay. We then investigated the role of HPSE1 in the invasive activity of MDA-MB-231 cells, which produce higher levels of hyaluronan (HA) and HS than non-invasive cells. Neither HS degradation, HA supplementation in Matrigel during Transwell migration, nor HPSE1 overexpression alone was sufficient to drive invasion, suggesting that invasive capacity depends on mesenchymal features and coordinated induction of HPSE1 and GAGs rather than HS degradation. Collectively, our findings demonstrate that AUF-mediated inhibition of aPKC suppresses HPSE1 expression, thereby inhibiting both its enzymatic and non-enzymatic functions and limiting cancer progression, metastasis, and angiogenesis. These results highlight the therapeutic potential of AUF for targeting HPSE1-driven tumor progression and support its repurposing for cancer treatment.
- Open Access
- 1 March 2026
- Published by International Institute of Anticancer Research in Cancer Genomics & Proteomics
- Vol. 23 (2) , 322-341
Co-expression of PKCζ and ALDH1A3 Is Associated With Poor Chemotherapeutic Responses in Basal-like Breast Cancer
The association between the expression of protein kinase C zeta (PKCζ) and chemotherapeutic responses among different subtypes of breast cancer has yet to be fully elucidated. The present study aimed to investigate the association between PKCζ expression and disease-specific survival (DSS) rates, with a particular focus on the influence of chemotherapy and cancer stem cell (CSC)-associated ALDH1A3 expression. Clinical and gene expression data from the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) dataset (n=2,509) were analyzed using Kaplan-Meier and Cox proportional hazards models. The findings were validated using The Cancer Genome Atlas (TCGA) Pan-Cancer Atlas dataset (n=1,084). In the METABRIC dataset, high PKCζ expression (PKCζ high) was associated with poor DSS rates in patients with the normal-like, claudin-low and basal-like subtypes treated with chemotherapy. Consistent results were obtained in TCGA dataset, where PKCζ high expression in basal-like breast cancer predicted poor prognosis, especially among patients treated with cyclophosphamide, an alkylating agent. Combined analysis further revealed that patients with high expression of both PKCζ and ALDH1A3 (PKCζ high/ALDH1A3 high) basal-like tumors treated with cyclophosphamide, doxorubicin, or fluorouracil had the worst DSS rates compared with other groups. In addition, PKCζ high/ALDH1A3 high basal-like tumors treated with anthracycline- or taxane-based regimens also exhibited poorer prognoses compared with other groups. PKCζ contributes to chemotherapeutic resistance, especially in patients with ALDH1A3-positive basal-like breast cancer, possibly through the regulation of CSC survival and proliferation. Moreover, PKCζ, either alone or in combination with ALDH1A3 expression, may serve as a prognostic biomarker for predicting the therapeutic efficacy of chemotherapy in basal-like breast cancer.
- 1 March 2026
- Published by International Institute of Anticancer Research in Cancer Genomics & Proteomics
- Vol. 23 (2) , 322-341
Open AccessCo-expression of PKCζ and ALDH1A3 Is Associated With Poor Chemotherapeutic Responses in Basal-like Breast Cancer
The association between the expression of protein kinase C zeta (PKCζ) and chemotherapeutic responses among different subtypes of breast cancer has yet to be fully elucidated. The present study aimed to investigate the association between PKCζ expression and disease-specific survival (DSS) rates, with a particular focus on the influence of chemotherapy and cancer stem cell (CSC)-associated ALDH1A3 expression. Clinical and gene expression data from the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC) dataset (n=2,509) were analyzed using Kaplan-Meier and Cox proportional hazards models. The findings were validated using The Cancer Genome Atlas (TCGA) Pan-Cancer Atlas dataset (n=1,084). In the METABRIC dataset, high PKCζ expression (PKCζ high) was associated with poor DSS rates in patients with the normal-like, claudin-low and basal-like subtypes treated with chemotherapy. Consistent results were obtained in TCGA dataset, where PKCζ high expression in basal-like breast cancer predicted poor prognosis, especially among patients treated with cyclophosphamide, an alkylating agent. Combined analysis further revealed that patients with high expression of both PKCζ and ALDH1A3 (PKCζ high/ALDH1A3 high) basal-like tumors treated with cyclophosphamide, doxorubicin, or fluorouracil had the worst DSS rates compared with other groups. In addition, PKCζ high/ALDH1A3 high basal-like tumors treated with anthracycline- or taxane-based regimens also exhibited poorer prognoses compared with other groups. PKCζ contributes to chemotherapeutic resistance, especially in patients with ALDH1A3-positive basal-like breast cancer, possibly through the regulation of CSC survival and proliferation. Moreover, PKCζ, either alone or in combination with ALDH1A3 expression, may serve as a prognostic biomarker for predicting the therapeutic efficacy of chemotherapy in basal-like breast cancer.
- Open Access
- 1 November 2025
- Published by International Institute of Anticancer Research in Cancer Diagnosis & Prognosis
- Vol. 5 (6) , 677-697
High p62 and ALDH1A3 Reduce the Effectiveness of Endocrine Therapy in Luminal B Breast Cancer
Background/Aim: High expression of p62 and ALDH1A3 indicates a poor clinical outcome in luminal B breast cancer, and p62 is involved in the progression of ALDH1-positive luminal B breast cancer stem cells. However, the association between endocrine therapy and high p62 and ALDH1A3 expression, in luminal B breast cancer remains unclear. Materials and Methods: Two datasets with gene expression and clinical data for patients with primary breast cancer (METABRIC, n=2,509; The Cancer Genome Atlas, n=1,084) were downloaded and statistically analyzed. To evaluate the association between the p62 and ALDH1A3 expression levels and endocrine therapy, including tamoxifen and aromatase inhibitor, in patients with luminal B breast cancer, disease-specific survival was examined using Kaplan-Meier and multivariate Cox regression analyses. Results: Patients with p62high ALDH1A3high luminal B breast cancer treated with endocrine therapy exhibited a poor prognosis. Moreover, patients with p62high ALDH1A3high luminal B breast cancer treated with tamoxifen showed a trend towards a poor prognosis, but those treated with aromatase inhibitors showed a significantly poor prognosis. These results suggest that endocrine therapy, especially aromatase inhibitors, exhibits a reduced effectiveness against p62high ALDH1A3high luminal B tumors. Conclusion: p62 and ALDH1A3 could be used together as a prognostic biomarker for predicting the efficacy of endocrine therapy for luminal B breast cancer.
- 1 November 2025
- Published by International Institute of Anticancer Research in Cancer Diagnosis & Prognosis
- Vol. 5 (6) , 677-697
Open AccessHigh p62 and ALDH1A3 Reduce the Effectiveness of Endocrine Therapy in Luminal B Breast Cancer
Background/Aim: High expression of p62 and ALDH1A3 indicates a poor clinical outcome in luminal B breast cancer, and p62 is involved in the progression of ALDH1-positive luminal B breast cancer stem cells. However, the association between endocrine therapy and high p62 and ALDH1A3 expression, in luminal B breast cancer remains unclear. Materials and Methods: Two datasets with gene expression and clinical data for patients with primary breast cancer (METABRIC, n=2,509; The Cancer Genome Atlas, n=1,084) were downloaded and statistically analyzed. To evaluate the association between the p62 and ALDH1A3 expression levels and endocrine therapy, including tamoxifen and aromatase inhibitor, in patients with luminal B breast cancer, disease-specific survival was examined using Kaplan-Meier and multivariate Cox regression analyses. Results: Patients with p62high ALDH1A3high luminal B breast cancer treated with endocrine therapy exhibited a poor prognosis. Moreover, patients with p62high ALDH1A3high luminal B breast cancer treated with tamoxifen showed a trend towards a poor prognosis, but those treated with aromatase inhibitors showed a significantly poor prognosis. These results suggest that endocrine therapy, especially aromatase inhibitors, exhibits a reduced effectiveness against p62high ALDH1A3high luminal B tumors. Conclusion: p62 and ALDH1A3 could be used together as a prognostic biomarker for predicting the efficacy of endocrine therapy for luminal B breast cancer.
- Open Access
- 1 November 2025
- Published by International Institute of Anticancer Research in Cancer Diagnosis & Prognosis
- Vol. 5 (6) , 706-719
PKCζ, CTNNBIP1 and ALDH1A3 Expression in Luminal B Breast Cancer Indicates Decreased Hormone Therapy Effectiveness
Background/Aim: The role of catenin β interacting protein 1 (CTNNBIP1), a negative regulator of the canonical Wnt/β-catenin signaling pathway, in luminal A and B breast cancer stem cells treated with hormone therapy is unknown. This study investigated the relationship between CTNNBIP1 and aldehyde dehydrogenase 1 family member A3 (ALDH1A3) expression and its impact on disease-specific survival in luminal A and B breast cancer. Given that high protein kinase ζ (PKCζ) expression, together with elevated CTNNBIP1 or ALDH1A3, is linked to poor prognosis in luminal B tumors, we also examined their combined influence. Materials and Methods: Gene expression and clinical data from the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC; n=2,509) were analyzed using Kaplan-Meier and Cox proportional hazards models. Findings were validated with The Cancer Genome Atlas Pan-Cancer Atlas (TCGA; n=1,084). Results: CTNNBIP1highALDH1A3high indicated a poor prognosis in patients with luminal B breast cancer treated with hormone therapy in the METABRIC dataset and aromatase inhibitors as hormone therapy in the TCGA data set, suggesting that high CTNNBIP1 and ALDH1A3 expression contributed to decreased effectiveness of hormone therapy in patients with luminal B breast cancer. PKCζhighCTNNBIP1highALDH1A3high was associated with a poor prognosis in patients with luminal B breast cancer treated with hormone therapy and aromatase inhibitors, suggesting that high PKCζ, CTNNBIP1 and ALDH1A3 expression contributed to decreased effectiveness of hormone therapy in patients with luminal B breast cancer. Conclusion: PKCζ and CTNNBIP1 may be involved in the progression of ALDH1A3-positive luminal B breast cancer. In luminal B breast cancer, PKCζ, CTNNBIP1 and ALDH1A3 could serve as molecular drug targets and prognostic biomarkers to predict the effectiveness of hormone therapy.
- 1 November 2025
- Published by International Institute of Anticancer Research in Cancer Diagnosis & Prognosis
- Vol. 5 (6) , 706-719
Open AccessPKCζ, CTNNBIP1 and ALDH1A3 Expression in Luminal B Breast Cancer Indicates Decreased Hormone Therapy Effectiveness
Background/Aim: The role of catenin β interacting protein 1 (CTNNBIP1), a negative regulator of the canonical Wnt/β-catenin signaling pathway, in luminal A and B breast cancer stem cells treated with hormone therapy is unknown. This study investigated the relationship between CTNNBIP1 and aldehyde dehydrogenase 1 family member A3 (ALDH1A3) expression and its impact on disease-specific survival in luminal A and B breast cancer. Given that high protein kinase ζ (PKCζ) expression, together with elevated CTNNBIP1 or ALDH1A3, is linked to poor prognosis in luminal B tumors, we also examined their combined influence. Materials and Methods: Gene expression and clinical data from the Molecular Taxonomy of Breast Cancer International Consortium (METABRIC; n=2,509) were analyzed using Kaplan-Meier and Cox proportional hazards models. Findings were validated with The Cancer Genome Atlas Pan-Cancer Atlas (TCGA; n=1,084). Results: CTNNBIP1highALDH1A3high indicated a poor prognosis in patients with luminal B breast cancer treated with hormone therapy in the METABRIC dataset and aromatase inhibitors as hormone therapy in the TCGA data set, suggesting that high CTNNBIP1 and ALDH1A3 expression contributed to decreased effectiveness of hormone therapy in patients with luminal B breast cancer. PKCζhighCTNNBIP1highALDH1A3high was associated with a poor prognosis in patients with luminal B breast cancer treated with hormone therapy and aromatase inhibitors, suggesting that high PKCζ, CTNNBIP1 and ALDH1A3 expression contributed to decreased effectiveness of hormone therapy in patients with luminal B breast cancer. Conclusion: PKCζ and CTNNBIP1 may be involved in the progression of ALDH1A3-positive luminal B breast cancer. In luminal B breast cancer, PKCζ, CTNNBIP1 and ALDH1A3 could serve as molecular drug targets and prognostic biomarkers to predict the effectiveness of hormone therapy.
- Open Access
- 26 September 2025
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 45 (10) , 4357-4372
High Expression of PKCζ and ALDH1A3 Is Associated With Poor Prognosis in Luminal B Breast Cancer
Background/Aim: The relationship between the protein kinase C zeta (PKCζ) and aldehyde dehydrogenase 1 family member A3 (ALDH1A3) expression levels and endocrine therapy susceptibility in luminal A and luminal B breast cancer subtypes is unclear. Therefore, the present study aimed to analyze this relationship in terms of disease-specific survival. Materials and Methods: Open-source datasets with clinical and gene expression information (METABRIC, n=2509; and TCGA Pan-Cancer Atlas, n=1084) were downloaded and analyzed. Kaplan-Meier survival and Cox proportional hazard analyses were performed. Results: The results indicated that high PKCζ and ALDH1A3 expression levels were associated with a poor prognosis in patients with luminal B type breast cancer treated with endocrine therapy, including aromatase inhibitors. These results suggest that high expression of PKCζ and ALDH1A3 contributes to reduced effectiveness of endocrine therapy in patients with luminal B breast cancer. Conclusion: PKCζ may be involved in the progression of ALDH1A3-positive luminal B breast cancer. Furthermore, PKCζ and ALDH1A3 could serve as molecular targets and prognostic biomarkers for predicting the efficacy of endocrine therapy in patients with ALDH1A3 positive luminal B breast cancer.
- 26 September 2025
- Published by International Institute of Anticancer Research in Anticancer Research
- Vol. 45 (10) , 4357-4372
Open AccessHigh Expression of PKCζ and ALDH1A3 Is Associated With Poor Prognosis in Luminal B Breast Cancer
Background/Aim: The relationship between the protein kinase C zeta (PKCζ) and aldehyde dehydrogenase 1 family member A3 (ALDH1A3) expression levels and endocrine therapy susceptibility in luminal A and luminal B breast cancer subtypes is unclear. Therefore, the present study aimed to analyze this relationship in terms of disease-specific survival. Materials and Methods: Open-source datasets with clinical and gene expression information (METABRIC, n=2509; and TCGA Pan-Cancer Atlas, n=1084) were downloaded and analyzed. Kaplan-Meier survival and Cox proportional hazard analyses were performed. Results: The results indicated that high PKCζ and ALDH1A3 expression levels were associated with a poor prognosis in patients with luminal B type breast cancer treated with endocrine therapy, including aromatase inhibitors. These results suggest that high expression of PKCζ and ALDH1A3 contributes to reduced effectiveness of endocrine therapy in patients with luminal B breast cancer. Conclusion: PKCζ may be involved in the progression of ALDH1A3-positive luminal B breast cancer. Furthermore, PKCζ and ALDH1A3 could serve as molecular targets and prognostic biomarkers for predicting the efficacy of endocrine therapy in patients with ALDH1A3 positive luminal B breast cancer.
- Open Access
- 26 June 2025
- Published by International Institute of Anticancer Research in Cancer Genomics & Proteomics
- Vol. 22 (4) , 538-556
High Expression ofPKCζAndCTNNBIP1Is Associated With Poor Prognosis in Luminal B Breast Cancer
Background/Aim: The relationship between protein kinase C zeta (PKCζ) expression and medical treatment resistance in breast cancer subtypes is unclear. Therefore, the present study aimed to analyze this relationship using disease-specific survival. Materials and Methods: Open-source datasets with clinical and gene expression information (METABRIC, n=2509; and TCGA Pan-Cancer Atlas, n=1084) were downloaded and Kaplan-Meier survival and Cox proportional hazard analyses were performed. Results: High expression of PKCζ indicated a poor prognosis in patients with luminal B type treated with endocrine therapy and aromatase inhibitor as endocrine therapy. Furthermore, catenin beta interacting protein 1 (CTNNBIP1) was identified as a differentially expressed gene between the PKCζhigh and PKCζlow luminal B breast cancer cohorts treated with endocrine therapy and aromatase inhibitors. PKCζhighCTNNBIP1high luminal B breast cancer treated with endocrine therapy and aromatase inhibitor indicated a poor prognosis. These results suggest that PKCζ and CTNNBIP1 are involved in breast cancer progression and contribute to reduced susceptibility to endocrine therapy in the luminal B breast cancer subtype. Conclusion: PKCζ and CTNNBIP1 may serve as a prognostic biomarker for predicting the efficacy of endocrine therapy in the luminal B breast cancer.
- 26 June 2025
- Published by International Institute of Anticancer Research in Cancer Genomics & Proteomics
- Vol. 22 (4) , 538-556
Open AccessHigh Expression ofPKCζAndCTNNBIP1Is Associated With Poor Prognosis in Luminal B Breast Cancer
Background/Aim: The relationship between protein kinase C zeta (PKCζ) expression and medical treatment resistance in breast cancer subtypes is unclear. Therefore, the present study aimed to analyze this relationship using disease-specific survival. Materials and Methods: Open-source datasets with clinical and gene expression information (METABRIC, n=2509; and TCGA Pan-Cancer Atlas, n=1084) were downloaded and Kaplan-Meier survival and Cox proportional hazard analyses were performed. Results: High expression of PKCζ indicated a poor prognosis in patients with luminal B type treated with endocrine therapy and aromatase inhibitor as endocrine therapy. Furthermore, catenin beta interacting protein 1 (CTNNBIP1) was identified as a differentially expressed gene between the PKCζhigh and PKCζlow luminal B breast cancer cohorts treated with endocrine therapy and aromatase inhibitors. PKCζhighCTNNBIP1high luminal B breast cancer treated with endocrine therapy and aromatase inhibitor indicated a poor prognosis. These results suggest that PKCζ and CTNNBIP1 are involved in breast cancer progression and contribute to reduced susceptibility to endocrine therapy in the luminal B breast cancer subtype. Conclusion: PKCζ and CTNNBIP1 may serve as a prognostic biomarker for predicting the efficacy of endocrine therapy in the luminal B breast cancer.
- Open Access
- 22 April 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-17
Asymmetric cell division of ALDH1-positive cancer stem cells generates glycolytic metabolically diverse cell populations
Metabolic heterogeneity in various cancer cells within a tumor causes resistance to medical therapies and promotes tumor recurrence and metastasis. However, the mechanisms by which tumors acquire metabolic heterogeneity are poorly understood. Here, we revealed that PKCλ-dependent asymmetric division of ALDH1-positive cancer stem cells (CSCs) led to an uneven distribution of glycolytic capacity, which is crucial for understanding metabolic heterogeneity within a tumor. The rate-limiting enzyme PFKP and the metabolic probe CDG in glycolysis codistributed with the ALDH1A3 protein during the post-cell division phase, highlighting a mechanism for acquiring metabolic diversity. PKCλ deficiency reduced the asymmetric distribution of these proteins in ALDH1high cells with high ALDH1 activity, suggesting a fundamental role for PKCλ in metabolic heterogeneity. We identified 28 distinct distribution patterns combining PFKP and CDG distributions, demonstrating the complexity of glycolytic heterogeneity. Furthermore, validation and prediction of cell distribution patterns via a probabilistic model confirmed that PKCλ deficiency diminished glycolytic diversity in individual cells within a cancer cell colony generated from an ALDH1-positive CSC. These findings suggest that PKCλ-dependent asymmetric cell division of ALDH1-positive CSCs is crucial for glycolytic heterogeneity in cancer cells within a tumor, potentially offering new therapeutic targets against tumor resistance and metastasis.
- 22 April 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-17
Open AccessAsymmetric cell division of ALDH1-positive cancer stem cells generates glycolytic metabolically diverse cell populations
Metabolic heterogeneity in various cancer cells within a tumor causes resistance to medical therapies and promotes tumor recurrence and metastasis. However, the mechanisms by which tumors acquire metabolic heterogeneity are poorly understood. Here, we revealed that PKCλ-dependent asymmetric division of ALDH1-positive cancer stem cells (CSCs) led to an uneven distribution of glycolytic capacity, which is crucial for understanding metabolic heterogeneity within a tumor. The rate-limiting enzyme PFKP and the metabolic probe CDG in glycolysis codistributed with the ALDH1A3 protein during the post-cell division phase, highlighting a mechanism for acquiring metabolic diversity. PKCλ deficiency reduced the asymmetric distribution of these proteins in ALDH1high cells with high ALDH1 activity, suggesting a fundamental role for PKCλ in metabolic heterogeneity. We identified 28 distinct distribution patterns combining PFKP and CDG distributions, demonstrating the complexity of glycolytic heterogeneity. Furthermore, validation and prediction of cell distribution patterns via a probabilistic model confirmed that PKCλ deficiency diminished glycolytic diversity in individual cells within a cancer cell colony generated from an ALDH1-positive CSC. These findings suggest that PKCλ-dependent asymmetric cell division of ALDH1-positive CSCs is crucial for glycolytic heterogeneity in cancer cells within a tumor, potentially offering new therapeutic targets against tumor resistance and metastasis.
- Open Access
- 5 July 2024
- Published by Spandidos Publications in Oncology Letters
- Vol. 28 (3) , 1-16
Co‑expression of SLC20A1 and ALDH1A3 is associated with poor prognosis, and SLC20A1 is required for the survival of ALDH1‑positive pancreatic cancer stem cells
Solute carrier family 20 member 1 (SLC20A1) is a sodium/inorganic phosphate symporter, which has been identified as a prognostic marker in several types of cancer, including pancreatic cancer. However, to the best of our knowledge, the association between SLC20A1 expression and cancer stem cell (CSC) markers, such as aldehyde dehydrogenase 1 (ALDH1), in pancreatic ductal adenocarcinoma (PDAC), and the role of SLC20A1 in PDAC CSCs remains unclear. In the present study, a genomic dataset of primary pancreatic cancer (The Cancer Genome Atlas, Pan‑Cancer Atlas) was downloaded and analyzed. Kaplan‑Meier analysis and multivariate Cox regression analysis were performed to evaluate the overall survival, disease‑specific survival (DSS), disease‑free interval (DFI) and progression‑free interval (PFI). Subsequently, SLC20A1 small interfering RNA (siRNA) knockdown (KD) was induced in the PANC‑1 and MIA‑PaCa‑2 PDAC cell lines, and in sorted high ALDH1 activity (ALDH1high) cells, after which, cell viability, in vitro tumor sphere formation, cell death and caspase‑3 activity were examined. The results revealed that patients with high expression of SLC20A1 (SLC20A1high) at tumor stage I had a poor prognosis compared with patients with low expression of SLC20A1 (SLC20A1low) in terms of DSS, DFI and PFI. In addition, patients with high expression of SLC20A1 and ALDH1A3 (SLC20A1highALDH1A3high) exhibited poorer clinical outcomes than patients with high expression of SLC20A1 and low expression of ALDH1A3 (SLC20A1highALDH1A3low), low expression of SLC20A1 and high expression of ALDH1A3 (SLC20A1lowALDH1A3high) and SLC20A1lowALDH1A3low. SLC20A1 siRNA KD in ALDH1high cells isolated from PANC‑1 and MIA‑PaCa‑2 cell lines resulted in suppression of in vitro tumorsphere formation, and enhancement of cell death and caspase‑3 activity. These results suggested that SLC20A1 was involved in cell survival via the suppression of caspase‑3‑dependent apoptosis, and contributed to cancer progression and poor clinical outcomes in PDAC. In conclusion, SLC20A1 may be used as a prognostic marker and novel therapeutic target of ALDH1‑positive pancreatic CSCs.
- 5 July 2024
- Published by Spandidos Publications in Oncology Letters
- Vol. 28 (3) , 1-16
Open AccessCo‑expression of SLC20A1 and ALDH1A3 is associated with poor prognosis, and SLC20A1 is required for the survival of ALDH1‑positive pancreatic cancer stem cells
Solute carrier family 20 member 1 (SLC20A1) is a sodium/inorganic phosphate symporter, which has been identified as a prognostic marker in several types of cancer, including pancreatic cancer. However, to the best of our knowledge, the association between SLC20A1 expression and cancer stem cell (CSC) markers, such as aldehyde dehydrogenase 1 (ALDH1), in pancreatic ductal adenocarcinoma (PDAC), and the role of SLC20A1 in PDAC CSCs remains unclear. In the present study, a genomic dataset of primary pancreatic cancer (The Cancer Genome Atlas, Pan‑Cancer Atlas) was downloaded and analyzed. Kaplan‑Meier analysis and multivariate Cox regression analysis were performed to evaluate the overall survival, disease‑specific survival (DSS), disease‑free interval (DFI) and progression‑free interval (PFI). Subsequently, SLC20A1 small interfering RNA (siRNA) knockdown (KD) was induced in the PANC‑1 and MIA‑PaCa‑2 PDAC cell lines, and in sorted high ALDH1 activity (ALDH1high) cells, after which, cell viability, in vitro tumor sphere formation, cell death and caspase‑3 activity were examined. The results revealed that patients with high expression of SLC20A1 (SLC20A1high) at tumor stage I had a poor prognosis compared with patients with low expression of SLC20A1 (SLC20A1low) in terms of DSS, DFI and PFI. In addition, patients with high expression of SLC20A1 and ALDH1A3 (SLC20A1highALDH1A3high) exhibited poorer clinical outcomes than patients with high expression of SLC20A1 and low expression of ALDH1A3 (SLC20A1highALDH1A3low), low expression of SLC20A1 and high expression of ALDH1A3 (SLC20A1lowALDH1A3high) and SLC20A1lowALDH1A3low. SLC20A1 siRNA KD in ALDH1high cells isolated from PANC‑1 and MIA‑PaCa‑2 cell lines resulted in suppression of in vitro tumorsphere formation, and enhancement of cell death and caspase‑3 activity. These results suggested that SLC20A1 was involved in cell survival via the suppression of caspase‑3‑dependent apoptosis, and contributed to cancer progression and poor clinical outcomes in PDAC. In conclusion, SLC20A1 may be used as a prognostic marker and novel therapeutic target of ALDH1‑positive pancreatic CSCs.